A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.

ABSTRACT: The adoptive transfer of T cells engineered with a chimeric antigen receptor (CAR) (hereafter referred to as CAR-T cells) specific for the B lymphocyte antigen CD19 has shown impressive clinical responses in patients with refractory B cell malignancies. However, the therapeutic effects of CAR-T cells that target other malignancies have not yet resulted in significant clinical benefit. Although inefficient tumor trafficking and various immunosuppressive mechanisms can impede CAR-T cell effector responses, the signals delivered by the current CAR constructs may still be insufficient to fully activate antitumor T cell functions. Optimal T cell activation and proliferation requires multiple signals, including T cell receptor (TCR) engagement (signal 1), co-stimulation (signal 2) and cytokine e

SUBMITTER: Kagoya Y 

PROVIDER: S-EPMC5839992 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature